ABSTRACT
AIM: To explore the clinical value of serum soluble intercellular adhesion molecule-1 (sICAM-1) in patients with primary hepatocellular carcinoma (PHC) and its relationship with liver fibrosis. METHODS: The serun sICAM-1, PC III, IV-C, LN and HA level of 45 cases of patients with PHC, 30 cases of benign tumor and 35 cases of healthy people were determined by ELISA, the relationship between sICAM-1 and liver fibrosis was analyzed. RESULTS: The serum sICAM-1, PC III, IV-C, LN and HA levels of the PHC group were significantly higher than that of the benign tumor group and normal control group, compared the difference was significant (P<0.05); The serum markers was no significant difference between the benign tumor group and normal control group (P>0.05); The serum sICAM-1 was positively correlated with the PC III, IV-C, LN and HA (γ= 0.683, 0.575, 0.573 and 0.539, P<0.05). CONCLUSION: Detection of serum sICAM-1 has important clinical significance for assessing the PHC patient's condition, early diagnosing and treating liver cancer.
Subject(s)
Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/pathology , Intercellular Adhesion Molecule-1/blood , Liver Cirrhosis/blood , Liver Cirrhosis/pathology , Liver Neoplasms/blood , Liver Neoplasms/pathology , Adult , Aged , Collagen Type III/blood , Female , Humans , Male , Middle Aged , PrognosisABSTRACT
BACKGROUND & OBJECTIVE: It has been confirmed that calcium folinate (CF), as a chemotherapy-biochemical modulator of 5-fluorouracil (5-FU), can improve the effect of antitumor of 5-FU. But the usage and dosage of this therapy should be further studied. The purpose of this article was to study the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of human body to simultaneously intravenous infusion of 5-FU and CF. METHODS: The cases being up to the selecting standard were treated with DDP+CF/5-FU regimen. The dose of CF and DDP for every course was fixed. The first dose of 5-FU was 500 mg x (m(2) x d)(-1),then the doses were increased by degree of 50 mg x (m(2) x d)(-1), if no severe side effect was observed, up to maximum toxicity tolerated dose. There were 3-6 cases in each degree of dose. RESULTS: Thirty-two cases were treated and given total 64 courses of the administration in all. The overall remission rate was 84.4%. The MTD of 5-FU was 800 mg x (m(2) x d)(-1). Mucositis and diarrhea were found to be the DLT. CONCLUSION: Simultaneous continuous infusion of 5-FU and CF can enhance the dosage of 5-FU, and has a better efficacy to advanced digestive tract, head and neck cancers. So the authors recommend that the dosage of 5-FU in phase II clinical trial is 700 mg x (m(2) x d)(-1). This dose can be used for 5 consecutive days and be repeated after 3 weeks.
